On April 20, 2017 Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, reported that the Company will release its first quarter 2017 financial results on Monday, May 8, 2017 (Press release, Epizyme, APR 20, 2017, View Source [SID1234518644]). Schedule your 30 min Free 1stOncology Demo! Epizyme also announced that two posters on interim efficacy and safety data from its ongoing Phase 2 study of tazemetostat in adult patients with molecularly defined solid tumor will be presented on June 6, 2017 at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago. The Company plans to hold a conference call to discuss the interim findings on Thursday, May 18, 2017 at 8:30 a.m. ET, after the ASCO (Free ASCO Whitepaper) abstracts have been released.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Considering the planned conference call, Epizyme will not host a separate conference call to discuss its first quarter 2017 financial results.
The Phase 2 data posters will be presented in the ASCO (Free ASCO Whitepaper) session listed below:
Sarcoma Cancer: General Poster Session
Sunday, June 4, 2017, 8:00 a.m. – 11:30 a.m. CDT
Abstract No.: 11058, Poster Board No.: 381
Title: Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950)
Location: Hall A
Sarcoma Cancer: General Poster Session
Sunday, June 4, 2017, 8:00 a.m. – 11:30 a.m. CDT
Abstract No.: 11057, Poster Board No.: 380
Title: Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with synovial sarcoma (NCT02601950)
Location: Hall A
About the Tazemetostat Clinical Trial Program
Tazemetostat, a first-in-class EZH2 inhibitor, is currently being studied in ongoing phase 2 programs in non-Hodgkin lymphoma (NHL), certain genetically defined solid tumors, including INI1-negative and SMARCA4-negative tumors and synovial sarcoma, and mesothelioma.